Interleukin 13 (IL13) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 13 (IL13) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 13 (IL13) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 13 (IL13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 13 (IL13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 13 (IL13)

The report reviews Interleukin 13 (IL13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 13 (IL13) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 13 (IL13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 13 (IL13) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 13 (IL13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 13 (IL13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Celgene Corporation

Cell Medica Limited

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

MedImmune, LLC

Molecular Partners AG

Neovacs SA

Novartis AG

Sanofi

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Interleukin 13 (IL13) Overview 7

Therapeutics Development 8

Interleukin 13 (IL13) - Products under Development by Stage of Development 8

Interleukin 13 (IL13) - Products under Development by Therapy Area 9

Interleukin 13 (IL13) - Products under Development by Indication 10

Interleukin 13 (IL13) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Interleukin 13 (IL13) - Products under Development by Companies 13

Interleukin 13 (IL13) - Products under Development by Universities/Institutes 15

Interleukin 13 (IL13) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Interleukin 13 (IL13) - Companies Involved in Therapeutics Development 23

Celgene Corporation 23

Cell Medica Limited 24

F. Hoffmann-La Roche Ltd. 25

GlaxoSmithKline Plc 26

MedImmune, LLC 27

Molecular Partners AG 28

Neovacs SA 29

Novartis AG 30

Sanofi 31

Interleukin 13 (IL13) - Drug Profiles 32

(dectrekumab + VAK-694) - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dectrekumab - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

lebrikizumab - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Monoclonal Antibody to Inhibit IL-5 and IL-13 for Asthma - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Recombinant Protein to Inhibit IL-13 and IL-17 for Respiratory Disease - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

RPC-4046 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SAR-156597 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

tralokinumab - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Interleukin 13 (IL13) - Dormant Projects 48

Interleukin 13 (IL13) - Discontinued Products 50

Interleukin 13 (IL13) - Featured News & Press Releases 51

Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 51

Feb 29, 2016: Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma 52

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 53

Aug 14, 2014: AstraZeneca advances tralokinumab to Phase III in severe asthma 53

May 12, 2014: AstraZeneca to present respiratory data on tralokinumab at ATS 2014 International Conference 54

Mar 05, 2014: Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma 55

Aug 04, 2011: Roche’s Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study 56

Apr 15, 2008: MedImmune Advances Asthma Program With Start Of A Phase 2 Trial In Europe And Australia And First U.S.-Based Clinical Trial For Antibody Targeting IL-13 57

Mar 18, 2008: MedImmune Advances Clinical Development Of Antibody Targeting Interleukin-9 In Patients With Asthma 58

May 25, 2005: Preclinical Data Support Link Between IL-9 And Airway Hyper-responsiveness Associated With Asthma 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Celgene Corporation, H2 2016 23

Pipeline by Cell Medica Limited, H2 2016 24

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25

Pipeline by GlaxoSmithKline Plc, H2 2016 26

Pipeline by MedImmune, LLC, H2 2016 27

Pipeline by Molecular Partners AG, H2 2016 28

Pipeline by Neovacs SA, H2 2016 29

Pipeline by Novartis AG, H2 2016 30

Pipeline by Sanofi, H2 2016 31

Dormant Projects, H2 2016 48

Dormant Projects (Contd..1), H2 2016 49

Discontinued Products, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports